AJP - Endo Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 285: E1174-E1181, 2003. First published August 21, 2003; doi:10.1152/ajpendo.00279.2003
0193-1849/03 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
285/6/E1174    most recent
00279.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (39)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perseghin, G.
Right arrow Articles by Luzi, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perseghin, G.
Right arrow Articles by Luzi, L.

Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes

Gianluca Perseghin,1,5 Guido Lattuada,1 Massimo Danna,3,4,5 Lucia Piceni Sereni,1 Paola Maffi,2 Francesco De Cobelli,4,5 Alberto Battezzati,1,6 Antonio Secchi,2 Alessandro Del Maschio,4,5 and Livio Luzi1,5,6,7

Sections of 1Nutrition/Metabolism and 2Organ Transplantation, Internal Medicine, 3Division of Nuclear Medicine, 4Division of Diagnostic Radiology, and 5Unit of Clinical Spectroscopy, Università Vita e Salute San Raffaele IRCCS H San Raffaele, 20132 Milan; and 6International Center for the Assessment of Nutritional Status, and 7Faculty of Exercise Sciences, Università degli Studi di Milano, 20100 Milan, Italy

Submitted 19 June 2003 ; accepted in final form 19 August 2003

Insulin resistance is a key pathogenic factor of type 2 diabetes (T2DM); in contrast, in type 1 diabetes (T1DM) it is considered a secondary alteration. Increased intramyocellular lipid (IMCL) content accumulation and reduced plasma adiponectin were suggested to be pathogenic events of insulin resistance in T2DM. This study was designed to assess whether IMCL content and plasma adiponectin were also associated with the severity of insulin resistance in T1DM. We studied 18 patients with T1DM, 7 older and overweight/obese patients with T2DM, and 15 nondiabetic, insulin-resistant offspring of T2DM parents (OFF) and 15 healthy individuals (NOR) as appropriate control groups matched for anthropometric features with T1DM patients by means of the euglycemic hyperinsulinemic clamp combined with the infusion of [6,6-2H2]glucose and 1H magnetic resonance spectroscopy of the calf muscles. T1DM and T2DM patients showed reduced insulin-stimulated glucose metabolic clearance rate (MCR: 5.1 ± 0.6 and 3.2 ± 0.8 ml · kg–1 · min–1) similar to OFF (5.3 ± 0.4 ml · kg–1 · min–1) compared with NOR (8.5 ± 0.5 ml · kg–1 · min–1, P < 0.001). Soleus IMCL content was increased in T1DM (112 ± 15 AU), T2DM (108 ± 10 AU) and OFF (82 ± 13 AU) compared with NOR (52 ± 7 AU, P < 0.05) and the result was inversely proportional to the MCR (R2 = 0.27, P < 0.001); an association between IMCL content and Hb A1c was found only in T1DM (R2 = 0.57, P < 0.001). Fasting plasma adiponectin was reduced in T2DM (7 ± 1 µg/ml, P = 0.01) and OFF (11 ± 1 µg/ml, P = 0.03) but not in T1DM (25 ± 6 µg/ml), whose plasma level was increased with respect to both OFF (P = 0.03) and NOR (16 ± 2 µg/ml, P = 0.05). In conclusion, in T1DM, T2DM, and OFF, IMCL content was associated with insulin resistance, demonstrating that IMCL accretion is a marker of insulin resistance common to both primary genetically determined and secondary metabolic (chronic hyperglycemia) alterations. The increased adiponectin levels in insulin-resistant patients with T1DM, in contrast to the reduced levels found in patients with T2DM and in OFF, demonstrated that the relationship of adiponectin to insulin resistance in humans is still unclear.

intramyocellular triglyceride content; leptin; magnetic resonance spectroscopy



Address for reprint requests and other correspondence: G. Perseghin, Internal Medicine, Section of Nutrition/Metabolism & Unit of Clinical Spectroscopy, via Olgettina 60, 20132 Milan, Italy (E-mail: perseghin.gianluca{at}hsr.it).




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
H.-Y. Liu, S. Y. Cao, T. Hong, J. Han, Z. Liu, and W. Cao
Insulin Is a Stronger Inducer of Insulin Resistance than Hyperglycemia in Mice with Type 1 Diabetes Mellitus (T1DM)
J. Biol. Chem., October 2, 2009; 284(40): 27090 - 27100.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
L. L. Guo, Y. Pan, and H. M. Jin
Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan
Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1876 - 1883.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
M. P. Krause, M. C. Riddell, C. S. Gordon, S. A. Imam, E. Cafarelli, and T. J. Hawke
Diabetic myopathy differs between Ins2Akita+/- and streptozotocin-induced Type 1 diabetic models
J Appl Physiol, May 1, 2009; 106(5): 1650 - 1659.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
S. Hammer, J. T. Jonker, H. J. Lamb, R. W. van der Meer, W. Zondag, J. M. Sepers, A. de Roos, J. W.A. Smit, and J. A. Romijn
Short-Term Hyperglycemic Dysregulation in Patients With Type 1 Diabetes Does Not Change Myocardial Triglyceride Content or Myocardial Function
Diabetes Care, August 1, 2008; 31(8): 1613 - 1614.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
E.-G. Hong, D. Y. Jung, H. J. Ko, Z. Zhang, Z. Ma, J. Y. Jun, J. H. Kim, A. D. Sumner, T. C. Vary, T. W. Gardner, et al.
Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling
Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1687 - E1696.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
T. J. Orchard, T. Costacou, A. Kretowski, and R. W. Nesto
Type 1 diabetes and coronary artery disease.
Diabetes Care, November 1, 2006; 29(11): 2528 - 2538.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
M. D. Jensen
Adipose tissue as an endocrine organ: implications of its distribution on free fatty acid metabolism
Eur. Heart J. Suppl., May 1, 2006; 8(suppl_B): B13 - B19.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
R. Stettler, M. Ith, K. J. Acheson, J. Decombaz, C. Boesch, L. Tappy, and C. Binnert
Interaction Between Dietary Lipids and Physical Inactivity on Insulin Sensitivity and on Intramyocellular Lipids in Healthy Men
Diabetes Care, June 1, 2005; 28(6): 1404 - 1409.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2003 by the American Physiological Society.